177-Lu LNC 1004
Alternative Names: 177-Lu LNC-1004Latest Information Update: 28 Dec 2023
At a glance
- Originator Yantai LNC Biotechnology
- Class Antineoplastics; Drug conjugates; Quinolines; Radioisotopes; Radiopharmaceuticals; Small molecules
- Mechanism of Action Fibroblast activation protein antagonists; Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 03 Oct 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Singapore (IV) (NCT05723640)
- 13 Feb 2023 Yantai LNC Biotechnology plans a phase-I trial for Solid tumours (Late-stage disease, Metastatic disease) in Singapore (IV) in March 2023 (NCT05723640)
- 17 Jan 2023 Preclinical trials in Solid tumours in Singapore (Parenteral) before January 2023